Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upjohn Laboratories

Division of Pfizer Inc.

Latest From Upjohn Laboratories

When Curtain Falls: 4+7 To 4+N Signals End To Branded Generics In China?

After only two multinationals managed to win bids in China's massive new centralized drug procurement scheme, other foreign firms were hoping to get a break in the second round. But this may not materialize.

China Commercial

Pfizer/Mylan: Pending Clash Of Quality Systems Could Determine Fate Of New Firm

After years of Mylan’s “one quality standard,” the merger with Pfizer Upjohn brings another. Which will prevail? Which should prevail?

Manufacturing Quality

Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

Deals M & A

Biocon Expects US Success For Biosimilar Trastuzumab Despite Amgen Launch

Leading Indian biologics firm Biocon reported first-quarter net profit soared more than 70% and said it is confident of a “very successful” US biosimilar trastuzumab launch, despite rival Amgen stealing a march by commercializing its own version first in the world’s largest drug market.

 

India Biosimilars
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register